First generic multiple sclerosis drug, made in Cambridge, launches

Cambridge-based Momenta Pharmaceuticals and partner Sandoz announced plans late yesterday to launch the first generic drug in the U.S. to treat multiple sclerosis, priced 15 percent less than the branded version of the drug. Momenta (Nasdaq: MNTA) developed the generic of the 20 milligram dosage of Copaxone, a once-a-day injectable drug by Israel-based Teva Pharmaceuticals (Nasdaq: TEVA) that generated $4.2 billion in revenue last year. The Cambridge biotech has partnered with Sandoz, the generics…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news